Skip to main content
logo
Vaxcell-Bio Therapeutics Co., Ltd. (KOSDAQ:323990)
South Korea flag South Korea · Delayed Price · Currency is KRW
4,000.00
+35.00 (0.88%)
Jul 21, 2026, 3:30 PM KST

Vaxcell-Bio Therapeutics Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
1,89913.72---
Revenue Growth (YoY)
13737.28%----
Cost of Revenue
1,53710.4416.4319.375.39
Gross Profit
361.573.28-16.43-19.37-5.39
Selling, General & Admin
8,0026,1715,7933,8112,714
Research & Development
6,0404,9192,0751,8101,350
Other Operating Expenses
2320.6716.626.570.44
Operating Expenses
15,44311,5108,1965,8854,250
Operating Income
-15,081-11,507-8,213-5,904-4,255
Interest Expense
-225.12-43.66-16.68-26.9-34.9
Interest & Investment Income
2,6201,155421.91322.31109.72
Currency Exchange Gain (Loss)
-1.51-11.69---
Other Non Operating Income (Expenses)
2,304259.95982.37846.11196.05
EBT Excluding Unusual Items
-10,384-10,147-6,825-4,763-3,984
Gain (Loss) on Sale of Investments
-182.7-126.84---
Gain (Loss) on Sale of Assets
-56.65--0.05-0.25-
Pretax Income
-10,624-10,274-6,825-4,763-3,984
Net Income
-10,624-10,274-6,825-4,763-3,984
Net Income to Common
-10,624-10,274-6,825-4,763-3,984
Shares Outstanding (Basic)
232015157
Shares Outstanding (Diluted)
232015157
Shares Change (YoY)
17.03%28.80%0.68%122.02%55.35%
EPS (Basic)
-463.00-524.00-448.34-315.00-585.00
EPS (Diluted)
-463.00-524.00-448.34-315.00-585.00
Free Cash Flow
-12,824-9,589-6,212-6,785-3,330
Free Cash Flow Per Share
-558.88-489.05-408.07-448.78-488.95
Gross Margin
19.04%23.90%---
Operating Margin
-794.20%-83851.26%---
Profit Margin
-559.45%-74865.84%---
Free Cash Flow Margin
-675.31%-69872.25%---
EBITDA
-13,616-11,107-7,901-5,647-4,070
D&A For EBITDA
1,466399.68311.34257.25185.31
EBIT
-15,081-11,507-8,213-5,904-4,255
Advertising Expenses
409.677.5538.41219.76